Halozyme Therapeutics Inc (HALO)

[rod5247]

Ludwig N. Hantson - President, BioScience
So with respect to HYQVIA we are really pleased with the approval and we’re gearing up as was mentioned. We are planning to ship product next week and that’s on target. When our goal for HYQVIA is to be the preferred and leading subcu treatment for PID and that should be supported by differentiation and we plan to expand HYQVIA into neurological indications in the coming year, so beyond PID.

At this moment there is a broad market awareness, there is high interest from physicians patients on HYQVIA and we are expecting accelerated sales in Q4. Which respect to pricing we’re introducing HYQVIA to the PBMs and the payers as we speak. Our pricing strategy is consistent with HYQVIA’s differentiated and unique value which is to provide subcu IG treatment that can be administered once a month. A dose is equivalent to that of IV IG. So with respect to the price consistent with Europe we will be launching at a price premium.

From Seeking Alpha transcript